Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 47,918 Shares

Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab sold 47,918 shares of the business’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $44.50, for a total transaction of $2,132,351.00. Following the transaction, the executive vice president owned 616,106 shares in the company, valued at approximately $27,416,717. This trade represents a 7.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Dana Aftab also recently made the following trade(s):

• On Thursday, February 19th, Dana Aftab sold 29,873 shares of Exelixis stock. The stock was sold at an average price of $44.35, for a total transaction of $1,324,867.55.

Exelixis Price Performance

Shares of NASDAQ EXEL traded down $0.47 during midday trading on Thursday, reaching $44.28. The company’s stock had a trading volume of 2,713,840 shares, compared to its average volume of 2,634,991. The stock has a market capitalization of $11.50 billion, a P/E ratio of 15.99, a PEG ratio of 1.02 and a beta of 0.42. The firm has a 50 day moving average price of $44.06 and a 200-day moving average price of $41.37. Exelixis, Inc. has a 12-month low of $32.38 and a 12-month high of $49.62.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.20. The company had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.Exelixis’s revenue was up 5.6% on a year-over-year basis. During the same period last year, the business posted $0.55 earnings per share. On average, equities analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Police & Firemen s Retirement System of New Jersey increased its position in shares of Exelixis by 0.3% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 102,581 shares of the biotechnology company’s stock valued at $4,521,000 after buying an additional 274 shares during the period. Richardson Financial Services Inc. increased its holdings in Exelixis by 95.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 292 shares during the period. RHS Financial LLC lifted its stake in Exelixis by 2.4% in the 4th quarter. RHS Financial LLC now owns 12,619 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 293 shares in the last quarter. Meeder Advisory Services Inc. lifted its stake in Exelixis by 5.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 5,406 shares of the biotechnology company’s stock worth $237,000 after purchasing an additional 298 shares in the last quarter. Finally, Cim LLC boosted its holdings in Exelixis by 0.9% in the 3rd quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock valued at $1,462,000 after purchasing an additional 305 shares during the period. Institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on EXEL. Citigroup downgraded shares of Exelixis from a “market outperform” rating to an “underperform” rating in a report on Monday, January 5th. UBS Group set a $41.00 target price on shares of Exelixis in a research report on Monday, January 5th. Morgan Stanley raised their price target on shares of Exelixis from $48.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. TD Cowen reiterated a “buy” rating on shares of Exelixis in a research note on Wednesday, November 5th. Finally, Truist Financial set a $51.00 price objective on Exelixis in a report on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Exelixis has an average rating of “Hold” and an average target price of $47.11.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.